GlassScriptPhysician profile
Jane S Cohen
NPI 1417953514
$2,816.09
in general payments reported to CMS, 2019-2025
25 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $63.01 · 2021: $442 · 2022: $764 · 2023: $650 · 2024: $409 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.19 | 2021-2025 | Creon, Linzess, Viberzi |
| Novo Nordisk INC | $273.36 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $250.98 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $217.99 | 2022-2023 | |
| Lilly USA, LLC | $205.65 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $194.14 | 2021-2023 | Arexvy, Shingrix |
| Medtronic, INC. | $170.64 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $142.10 | 2022 | |
| Madrigal Pharmaceuticals | $140.15 | 2024 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $133.66 | 2022-2023 | Ocaliva |
| Idorsia Pharmaceuticals US INC | $120.85 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $114.22 | 2019 | |
| Astellas Pharma US INC | $89.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $47.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $46.80 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $40.19 | 2022-2023 | Zeposia |
| Amgen INC. | $35.92 | 2019-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.88 | 2019 | |
| Exact Sciences Corporation | $24.81 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $20.78 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $18.11 | 2022 | |
| Aimmune Therapeutics, INC. | $17.84 | 2024 | |
| Alvogen INC | $17.19 | 2023 | Teriparatide |
| Biohaven Pharmaceuticals, INC. | $16.31 | 2021 | |
| Sanofi Pasteur INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.